TWO COMPONENT STRATEGY FOR IMMUNE TARGETING
TWO COMPONENT STRATEGY FOR IMMUNE TARGETING
批准号:
2642824
负责人:
Edmund J Gosselin
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-07-01 至 2000-06-30
关键词:
T lymphocyte antibody formation antibody receptor antigen presentation antigen presenting cell binding proteins biotechnology biotin cell proliferation enzyme linked immunosorbent assay genetically modified animals immunoconjugates immunomodulators laboratory mouse leukocyte activation /transformation protein transport vaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Adapted from the investigator's abstract) Targeting
immunogens to antigen presenting cells (APC) significantly enhances T cell
activation and antibody production in vitro and in vivo, respectively,
eliminating the need for traditional adjuvants. This proposal focuses on
developing a biotin-binding Fcg receptor I (APC)-specific targeting
element linked to a biotinylated functional element (tetanus toxin C-
fragment). The ability of this anti-Fcg receptor I (FcgRI)-C-fragment
conjugate to enhance T cell activation in vitro and in vivo will be
demonstrated by monitoring T cell proliferation and cytokine production.
The ability of this conjugate to enhance antibody production in vivo will
be evaluated using human FcgRI transgenic mice which exhibit a cellular
distribution and density of FcgRI similar to that in humans. Following
immunization of transgenic mice with the anti-FcgRI-C-fragment conjugate,
biodistribution of the conjugate, as well as antibody production to it,
and its components will be monitored using radiolabeling and ELISA
techniques, respectively.
This two component approach to immune targeting promises to be safe,
extremely versatile, and cost effective. In addition, it will facilitate
the rapid evaluation and use of multiple targeting, antigen, and adjuvant
combinations, significantly advancing, and possibly revolutionizing,
current vaccine technology.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
An Adjuvant-Independent Dual-Targeted (Multi-Function) Mucosal Vaccine Platform
-
批准号:8911997
-
项目类别:
-
资助金额:$21.88万
-
财政年份:2015
-
负责人:Edmund J Gosselin
-
依托单位:
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting
-
批准号:9300826
-
项目类别:
-
资助金额:$58.4万
-
财政年份:2013
-
负责人:Edmund J Gosselin
-
依托单位:
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting
-
批准号:8443445
-
项目类别:
-
资助金额:$58.4万
-
财政年份:2013
-
负责人:Edmund J Gosselin
-
依托单位:
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting
-
批准号:8698271
-
项目类别:
-
资助金额:$58.4万
-
财政年份:2013
-
负责人:Edmund J Gosselin
-
依托单位:
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
-
批准号:8261081
-
项目类别:
-
资助金额:$38.47万
-
财政年份:2009
-
负责人:Edmund J Gosselin
-
依托单位:
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
-
批准号:7807054
-
项目类别:
-
资助金额:$38.86万
-
财政年份:2009
-
负责人:Edmund J Gosselin
-
依托单位:
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
-
批准号:7660124
-
项目类别:
-
资助金额:$37.83万
-
财政年份:2009
-
负责人:Edmund J Gosselin
-
依托单位:
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
-
批准号:8049731
-
项目类别:
-
资助金额:$38.47万
-
财政年份:2009
-
负责人:Edmund J Gosselin
-
依托单位:
Protective Activity of a Multi-Functional Immunogen
-
批准号:7195315
-
项目类别:
-
资助金额:$19.75万
-
财政年份:2007
-
负责人:Edmund J Gosselin
-
依托单位:
Protective Activity of a Multi-Functional Immunogen
-
批准号:7350212
-
项目类别:
-
资助金额:$22.45万
-
财政年份:2007
-
负责人:Edmund J Gosselin
-
依托单位:
ENHANCED T AND B CELL RESPONSES VIA RECOMBINANT PROTEINS
-
批准号:6213323
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2000
-
负责人:Edmund J Gosselin
-
依托单位:
ENHANCED T AND B CELL RESPONSES VIA RECOMBINANT PROTEINS
-
批准号:6374417
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2000
-
负责人:Edmund J Gosselin
-
依托单位:
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
-
批准号:2070930
-
项目类别:
-
资助金额:$10.71万
-
财政年份:1993
-
负责人:Edmund J Gosselin
-
依托单位:
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
-
批准号:3456540
-
项目类别:
-
资助金额:$9.84万
-
财政年份:1993
-
负责人:Edmund J Gosselin
-
依托单位:
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
-
批准号:2070929
-
项目类别:
-
资助金额:$9.82万
-
财政年份:1993
-
负责人:Edmund J Gosselin
-
依托单位:
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
-
批准号:2070931
-
项目类别:
-
资助金额:$11.12万
-
财政年份:1993
-
负责人:Edmund J Gosselin
-
依托单位:
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
-
批准号:2517242
-
项目类别:
-
资助金额:$11.55万
-
财政年份:1993
-
负责人:Edmund J Gosselin
-
依托单位:
Immunology Core
-
批准号:8698578
-
项目类别:
-
资助金额:$23.77万
-
财政年份:--
-
负责人:Edmund J Gosselin
-
依托单位:
Immunology Core
-
批准号:8711178
-
项目类别:
-
资助金额:$21.43万
-
财政年份:--
-
负责人:Edmund J Gosselin
-
依托单位:
Redox Control of F. tularensis Pathogenesis
-
批准号:8711175
-
项目类别:
-
资助金额:$42.55万
-
财政年份:--
-
负责人:Edmund J Gosselin
-
依托单位:
海外基金